Recurrent chromosomal translocations producing a chimaeric MLL oncogene give rise to a highly aggressive acute leukaemia associated with poor clinical outcome 1 . The preferential involvement of chromatin-associated factors as MLL fusion partners belies a dependency on transcription control 2 . Despite recent progress made in targeting chromatin regulators in cancer 3 , available therapies for this well-characterized disease remain inadequate, prompting the need to identify new targets for therapeutic intervention. Here, using unbiased CRISPR-Cas9 technology to perform a genome-scale lossof-function screen in an MLL-AF4-positive acute leukaemia cell line, we identify ENL as an unrecognized gene that is specifically required for proliferation in vitro and in vivo. To explain the mechanistic role of ENL in leukaemia pathogenesis and dynamic transcription control, a chemical genetic strategy was developed to achieve targeted protein degradation. Acute loss of ENL suppressed the initiation and elongation of RNA polymerase II at active genes genome-wide, with pronounced effects at genes featuring a disproportionate ENL load. Notably, an intact YEATS chromatin-reader domain was essential for ENL-dependent leukaemic growth. Overall, these findings identify a dependency factor in acute leukaemia and suggest a mechanistic rationale for disrupting the YEATS domain in disease.
which given recent determination of the YEATS domain as an acyllysine reader module [17] [18] [19] [20] , prompted further investigation. ENL has been implicated in transcription control as a core component of the super elongation complex (SEC) [21] [22] [23] [24] [25] , which also includes the positive transcription elongation factor b (P-TEFb) heterodimer (CDK9 and cyclin T1). ENL has also been suggested to interact directly with DOT1L [21] [22] [23] , a histone methyltransferase crucial for the development and maintenance of MLL-fusion leukaemia 7, 9, 11, 12 , altogether supporting a rationale for ENL in MLL pathogenesis.
To validate ENL as a growth requirement, four additional sgRNAs were designed ( Fig. 1b) and tested alongside the ENL-targeted sequence most highly depleted in the initial screen (ENL-sg1). Each was confirmed to mediate on-target Cas9 activity against ENL (Extended Data Fig. 1b ), inhibiting competitive growth of MV4;11 cells similarly to the loss of FLT3 ( Fig. 1c and Extended Data Fig. 1c, d) , a bona fide target in the FLT3-ITD-positive cell line 15 . Of the seven additional cell lines tested, each of which comparably express ENL (Extended Data Fig. 1e ), the SEMK2 (MLL-AF4 acute lymphoid leukaemia (ALL)), OCI/AML-2 (MLL-AF6 AML), MOLM-13 (MLL-AF9 AML), NOMO-1 (MLL-AF9 AML) and SKM-1 (MLL wild-type AML) cell lines were sensitive to ENL loss, whereas only HL-60 (MLL wild-type AML) and JURKAT (T-ALL) cells were not (Fig. 1d , e and Extended Data Fig. 1f-j) . Furthermore, an MV4;11 xenotransplantation model of disseminated leukaemia in mice was sensitive to ENL loss, exhibiting marked reductions in disease progression and an overall survival benefit with CRISPR-Cas9 targeting ( Fig. 1f-h) . By contrast, competitive growth assays revealed that proliferation of Lin − Sca-1 + c-Kit + (LSK) mouse haematopoietic progenitors was minimally affected by Enl loss (Fig. 1i , Extended Data Fig. 2a, b ), qualifying ENL for further consideration as a leukaemia target. Notably, but consistent with the initial CRISPR-Cas9 knockout screen results, loss of the highly homologous YEATS-containing protein, AF9, had no observable anti-proliferative effects in MV4;11 or MOLM-13 cells (Extended Data Fig. 1l ), suggesting a specific, unique requirement for ENL function in acute leukaemia.
Given the previous annotation of ENL as a transcriptional activator [21] [22] [23] [24] [25] , we proposed that ENL supports the pathogenesis of acute leukaemia via the maintenance of dysregulated gene expression. To test this hypothesis, we developed a new functional genetic strategy, building on phthalimide conjugation of small molecules as an approach to achieve targeted protein degradation 26 . To induce degradation of the ENL chimaera, FKBP12(F36V) was used as a protein tag for ENL, along with a hetero-bifunctional small molecule selectively targeting FKBP12(F36V) and the E3 ubiquitin ligase CRBN. Conveniently, the LETTER RESEARCH previously identified F36V mutation produces a 'hole' in the protein surface that accommodates a complementary steric 'bump' on the ligand 27 , thereby avoiding targeting of wild-type FKBP12.
With a haemagglutinin (HA) epitope tag used for detection, ENL was expressed as amino-and carboxy-terminal FKBP12(F36V) fusions in MV4;11-Cas9 cells and efficiently degraded at nanomolar concentrations by both dTAG-7 and dTAG-13 ( Fig. 2a and Extended Data Fig. 3a-d ), notably within 30 min and 1 h, respectively ( Fig. 2b and Extended Data Fig. 3e ). This system proved amenable for use in several cellular systems (Extended Data Fig. 3f -h), and durable over several days after a single treatment (Extended Data Fig. 3i , j), particularly with dTAG-13 treatment, which led to its selection for further characterization. Upon selective inactivation of endogenous ENL and clonal expansion of lines bearing N-and C-terminal fusions (Extended Data Fig. 4a , b), expression proteomics revealed exclusive loss of ENL with a single 3-h dTAG-13 exposure (Fig. 2c,) whereas wild-type FKBP12 is spared by this 'bump-hole' strategy.
Administration of dTAG produced dose-responsive decreases in viability and potently suppressed proliferation in the absence of endogenous ENL ( Fig. 2d and Extended Data Fig. 4c -f), with undetectable effects in wild-type MV4;11 cells (Extended Data Fig. 4g , h). We focused subsequent analyses on the C-terminally tagged MV4;11 cell line (Cas9 + , ENL-FKBP12(F36V)-HA + , ENL −/− ) as it featured a doubling time (31.3 h, least-squares nonlinear regression, R 2 = 0.956) closer to that of wild-type MV4;11 cells (25.8 h, R 2 = 0.994) than did the N-terminally tagged line (35.0 h, R 2 = 0.995). BrdU staining revealed that growth impairment downstream of pharmacological ENL degradation can be attributed to rapid induction of G1 arrest and an accumulation of sub-G1 cells over 72 h ( Fig. 2e and Extended Data Fig. 4i ).
Consistent with previous annotations of ENL as a transcriptional activator, we observed subtle loss of gene expression by cell-count normalized RNA sequencing (RNA-seq) at 8 h, followed by global downregulation of active transcripts at 24 and 96 h ( Fig. 2f ). We noted that several well-characterized leukaemic drivers, including HOXA10, MYC, MYB, and MEIS1, were among the earliest and most severely downregulated transcripts, whereas the myeloid differentiation marker ITGAM (also known as CD11b or MAC-1) was upregulated ( Fig. 2g ). Underlying global transcriptional defects at 24 h was a concomitant decrease in RNA Pol II abundance at transcription start sites (TSS) and gene bodies of active genes ( Fig. 2h , i).
By chromatin immunoprecipitation and next-generation DNA sequencing (ChIP-seq), we found genomic localization of ENL-FKBP12(F36V) (using an HA-directed antibody) in MV4;11 (Cas9 + , ENL-FKBP12(F36V)-HA, ENL −/− ) cells to be closely correlated with wild-type ENL in the parental MV4;11 cells (Extended Data Fig. 5a ), with each factor preferentially enriched at TSS ( Fig. 3a and Extended Data Fig. 5b , c). Enrichment also correlated with epigenomic localization of the reported YEATS-domain substrates [17] [18] [19] [20] H3K9ac, H3K18ac and H3K27ac (Extended Data Fig. 5d -i). Notably, ranking ENL-bound loci uncovered an asymmetric distribution of ENL on the genome in which a small fraction (ENL: 4.0%; ENL-FKBP: 2.5%) of all bound sites were enriched for a disproportionate amount of total ENL (ENL: 51.2%; ENL-FKBP: 50.1%) (Fig. 3b , c and Extended Data Fig. 5j ). Within the set of asymmetrically loaded targets, we identified a large number of leukaemogenic genes such as MYC, MYB, HOXA10 and MEIS1. A similar phenomenon was observed in MOLM-13 cells with preferential localization of ENL to promoters (Extended Data Fig. 6a ), notably correlated with H3K27ac enrichment (Extended Data Fig. 6b ; 
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GEO accession GSM1652920; ref. 28 ) and asymmetrically distributed on the genome (Extended Data Fig. 6c, d) .
By integrating these gene sets with kinetic gene expression profiling following dTAG-13 exposure, we uncovered preferential downregulation of asymmetrically enriched ENL target genes ( Fig. 3d and Extended Data Fig. 7a -c), prompting further interrogation of classspecific RNA Pol II dynamics at ENL target genes. By ChIP-seq with cell-count normalization (ChIP-Rx), we uncovered a preferential loss of RNA Pol II from the gene bodies of asymmetrically loaded targets, but with comparatively minimal effects at their TSS, reflecting a pause release defect at those genes ( Fig. 3e and Extended Data Fig. 7d, e ). Given previous characterization of ENL as a member of the SEC, we reasoned that these effects might be consequences of SEC recruitment to chromatin. To test this idea, we focused on the chromatin localization of AFF4 and CDK9, which are scaffolding and catalytic subunits of the SEC, respectively. After a 6-h treatment with dTAG-13, we uncovered an evident loss of AFF4 from promoters of asymmetrically, but not typically, loaded targets ( Fig. 3f , h, i and Extended Data Fig. 7f , i), which was also accompanied by a preferential loss of CDK9 from the promoters of those genes ( Fig. 3g -i and Extended Data Fig. 7g , i). This suggested that ENL may contribute to the recruitment of the SEC to asymmetrically loaded target genes to promote productive elongation. We thus focused on the catalytic output of CDK9 activity (phosphorylation of serine 2 (S2P) of the RNA Pol II C-terminal domain heptapeptide repeat) as a marker of elongating polymerase 29 . After 24 h of dTAG-13 treatment, we observed diminished Pol II S2P enrichment specifically within gene bodies of ENL targets with asymmetric enrichment (Fig. 3h, i and Extended Data Fig. 7h, i) .
As ENL has been reported to bind to DOT1L directly 21-23 , we explored the functional relationship between these two factors. The rapid anti-proliferative response to ENL destabilization suggests a mechanism distinct from DOT1L function, as both genetic and chemical targeting of DOT1L is characterized by a delayed (7-10 day) effect on MLL growth and viability 7, 9 . Indeed, bulk levels of H3K79me2 were minimally changed by ENL degradation and only modest effects on locus-specific H3K79me2 were observed at asymmetric ENL target genes by ChIP-seq (Extended Data Fig. 8a-c) . As any changes to H3K79me2 occur several days after the first gene-expression changes occur following ENL degradation (96 h versus 6 h), we interpret these effects as secondary events attributable to the effect of ENL loss. To dissect DOT1L-independent and DOT1L-dependent ENL phenotypes further, we leveraged the rapid kinetics afforded by the dTAG/ENL system, finding that cell cycle and gene expression effects after ENL degradation were antecedent to those induced by DOT1L inhibition (Extended Data Fig. 8d, e ). Moreover, combination treatments for 96 h revealed an additive effect on the suppression of MYC and HOXA9 transcription compared to either single agent treatment (Extended Data Fig. 8f ). Also, while we were able to reproduce previous reports that DOT1L inhibition specifically downregulates MLL fusion target genes 7,9 , we did not uncover preferential suppression of published MLL-AF4 target genes after dTAG-13 treatment, and MLL-AF4 target genes exhibit minimal overlap with asymmetrically loaded ENL targets 10, 30 (Extended Data Fig. 8g-i) . Together, these data suggest that ENL degradation produces anti-leukaemic effects on gene expression that occur, at least in part, through DOT1L-independent mechanisms. This agrees with the apparent ENL requirement in wild-type MLL acute leukaemia (Extended Data Fig. 1h ), whereas DOT1L is selectively required in MLL-rearranged leukaemia 7,9 . Given the evident addiction to ENL in acute leukaemia cells, we used saturating CRISPR-Cas9 mutagenesis to aid in the qualification of functionally relevant protein domains for drug-discovery efforts 31 . We observed strong negative selection from sgRNAs targeting all annotated 
regions of ENL, with no regions emerging as a clear outlier (Fig. 4a) . Given the sensitivity of CRISPR-Cas9 directed at the YEATS domain, and our positive experience approaching acetyl-lysine recognition motifs with discovery chemistry, we explored whether ENL-dependent growth was contingent on YEATS domain function. Informed by published structure-function studies of the highly homologous AF9 protein 17 , we engineered ENL mutations predicted to either minimally or severely affect acetyl-lysine recognition by featuring alanine 
replacements at Phe47 or Tyr78, respectively (Extended Data Fig. 9a ). As previously reported for AF9, we confirmed the ability of wild-type ENL to bind H3K9ac and H3K27ac, and although this interaction was moderately affected by mutation of Phe47 to alanine, ENL(Y78A) exhibited a nearly complete inability to bind acetyl-lysine ( Fig. 4b and Extended Data Fig. 9b-d) . Despite equivalent expression, unaffected nuclear localization, and thermal stability in MV4;11-Cas9 cells (Extended Data Fig. 9e-h) the ENL(F47A) and ENL(Y78A) mutants exhibited moderate and severe defects in the localization to chromatin, respectively ( Fig. 4c-e ). Ultimately, these findings are consistent with the ability of each construct to rescue loss of endogenous ENL (Fig. 4f) , providing genetic validation of the YEATS domain as a functional, emerging therapeutic target in leukaemia.
In advance of identifying direct-acting inhibitors of ENL, we present data in support of a facile chemical biology platform to study dynamic cellular processes. We anticipate broad applicability of this techno logy beyond the scope of this study. We use the dTAG system to study the 'fast biology' of transcription activation and elongation, capable of disentangling immediate versus secondary effects, complementing if not improving genetic perturbations (such as short interfering RNA (siRNA) and CRISPR). Together, these studies provide support for a DOT1L-independent mechanism of leukaemic maintenance, in which ENL recruitment of the SEC to promoters contributes to transactivation of as-yet undruggable oncogenes, such as MYC, MYB and HOXA10. Notably, although the role of ENL as a frequent fusion partner of MLL in leukaemia has been known 1 , we report wild-type ENL, and specifically its YEATS domain, as an unrecognized cancer-specific dependency target in acute leukaemia. We and others may now pursue the discovery of chromatin-competitive antagonists of the ENL YEATS domain, with mechanistic guidance, as leukaemia therapy.
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